Eiko Lifesciences Limited · BSE:EIKO
Eiko Lifesciences — Q1 FY2021-22 Earnings Presentation
19 slides from Eiko Lifesciences's earnings presentation, 2021
Slide 1: Investor's Presentation
INVESTOR’S PRESENTATION Eiko LifeSciences Limited (Formerly known as Narendra Investments (Delhi) Ltd.) Regd. Office Address: 604, Centrum, Opp. TMC Office, Near Satkar Grand Hotel, Wagle Estate, Thane MH 400604 Phone No.: 022-2539 0009; Email id: investor.relations@eikolifesciences.com BSE Code: Ei
Slide 2: Safe Harbor
SAFE HARBOR This presentation and the accompanying slides (the “Presentation”), which have been prepared by Eiko LifeSciences Limited (the “Company”), solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities and shall n
Slide 3: The Ethos - Vision and Mission
The Ethos- Vision and Mission 3
Slide 4: About the Company
ABOUT THE COMPANY Eiko LifeSciences Ltd., was originally Incorporated in 1977 (BSE Code: EIKO| 540204 |) has recently ventured in the business of Manufacturing, Supplying and Export of Speciality & Fine Chemicals. Company has successfully ventured in the business by amending the main object of the c
Slide 5: Company Overview
Company Overview 5
Slide 6: Company established in race of becoming India's leading speciality chemicals manufacturer
In a short span of time, company has established itself in the race of becoming India's leading Speciality & Fine Chemicals Manufacturer, Supplier & Exporting company. ➢ Company’s Speciality Chemicals product offerings comprise of Organic as well as and Inorganic chemicals. ➢ Its products are used i
Slide 7: Q-1/FY 21-22 Financial Performance
Q-1/ FY 21-22 Financial Performance 7
Slide 8: Financial Highlights (₹ in Lakhs)
Financial Highlights (₹ in Lakhs) Q1 Q4 Particulars FY2021-22 FY2020-21 % Change Total Income 857.19 628.15 36% EBIDTA 67.45 55.64 21% PBT 53.62 48.55 10% PAT 40.12 35.48 13% 8
Slide 9: Other Highlights of the Quarter
Other Highlights of the Quarter • During the quarter ended 30 June 2021, paid up Share capital of the company th increased from Rs. 3.82 Cr to Rs. 8.32 Cr on account of issuance and allotment of 24,29,967 New Equity Shares having a face value of Rs. 10/- each, issued for cash at Rs. 30/- per share a
Slide 10: Our Products & Business
Our Products & Business 10
Slide 11: Our Business Profile
OUR Business Profile Our Business is broadly categorized Company is also Intermediates for proposing to venture Pharmaceuticals, into APIs business, Fine Chemicals & as a part of forward Agrochemicals integration strategy 11
Slide 12: Our Products Profile
OUR Products Profile 3-Chloropropiophenone, Orthochlorobenzonitrile Fine Chemicals Agrochemicals intermediates (2-Chlorobenzonitrile Halogenated products such as used for perfumery, food & Used in manufacturing of Bromo/ Chloro derivatives of flavor Industry such as Coumarin Speciality Fungicides an
Slide 13: End Users of Our Products
End users of our Products 14
Slide 14: End-user industries
PHARMACEUTICALS NUTRACEUTICALS AGRO CHEMICALS CONSTRUCTION CHEMICALS DYES & PIGMENTS FLAVORS & FRAGRANCES
Slide 15: Competitive Advantages
Competitive Advantages 16
Slide 16: Eiko LifeSciences Ltd. Competitive Advantages
Eiko LifeSciences Ltd. has the following Competitive Advantages: Large and diverse array of products Strong relations with Manufacturing facilities Diversified and Stable Customer Base Strong Relations with Marquee Clients Experienced team with domain knowledge Established and stable relationship wi
Slide 17: Experienced Promoters, Board of Directors and KMPs
Experienced Promoters, Board of Directors and KMPs 18
Slide 18: Board of Directors
Operations of the Company are being professionally managed by a team of experienced technocrats under guidance from Board of Directors ➢ CA Laxmikant Kabra (Chairman, Promoter Director) ➢ Mr. Bhavesh Dhirajlal Tanna (Promoter Director) ➢ Mr. Umesh More (Executive Director) ➢ Ms. Kajal Kothari (Indep
Slide 19: Thanks! Any questions?
Thanks! Any questions? You can find us at: business@eikolifesciences.com 20
Eiko LifeSciences — Q1 FY2021-22 Earnings Presentation on 6ix